These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30993587)

  • 21. Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature.
    Berger GK; Gee K; Votruba C; McBride A; Anwer F
    Crit Rev Oncol Hematol; 2017 May; 113():8-17. PubMed ID: 28427526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
    Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
    Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
    Gibb A; Pirrie SJ; Linton K; Warbey V; Paterson K; Davies AJ; Collins GP; Menne T; McKay P; Fields PA; Miall FM; Nagy E; Wheatley K; Reed R; Baricevic-Jones I; Barrington S; Radford J
    Br J Haematol; 2021 Apr; 193(1):63-71. PubMed ID: 32926420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
    Horwitz SM; Advani RH; Bartlett NL; Jacobsen ED; Sharman JP; O'Connor OA; Siddiqi T; Kennedy DA; Oki Y
    Blood; 2014 May; 123(20):3095-100. PubMed ID: 24652992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab vedotin in CD30
    Enos TH; Feigenbaum LS; Wickless HW
    Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
    Han TH; Gopal AK; Ramchandren R; Goy A; Chen R; Matous JV; Cooper M; Grove LE; Alley SC; Lynch CM; O'Connor OA
    J Clin Pharmacol; 2013 Aug; 53(8):866-77. PubMed ID: 23754575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
    Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
    Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
    Oka S; Ono K; Nohgawa M
    Anticancer Drugs; 2020 Jun; 31(5):536-539. PubMed ID: 31934889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
    Popadic S; Lekic B; Tanasilovic S; Bosic M; Nikolic M
    Dermatol Ther; 2020 Jan; 33(1):e13152. PubMed ID: 31743946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD30 is a potential therapeutic target in malignant mesothelioma.
    Dabir S; Kresak A; Yang M; Fu P; Wildey G; Dowlati A
    Mol Cancer Ther; 2015 Mar; 14(3):740-6. PubMed ID: 25589494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
    Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
    Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].
    Maitrepierre F; Schissler C; Cribier B; Lipsker D
    Ann Dermatol Venereol; 2020 Mar; 147(3):198-201. PubMed ID: 31959414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
    Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
    Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.
    Suri A; Mould DR; Song G; Collins GP; Endres CJ; Gomez-Navarro J; Venkatakrishnan K
    Clin Pharmacol Ther; 2019 Dec; 106(6):1268-1279. PubMed ID: 31152605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
    Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
    J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
    [No Abstract]   [Full Text] [Related]  

  • 37. Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.
    Kang L; Jiang D; Ehlerding EB; Barnhart TE; Ni D; Engle JW; Wang R; Huang P; Xu X; Cai W
    Mol Pharm; 2018 Apr; 15(4):1627-1634. PubMed ID: 29537283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
    Li H; Han TH; Hunder NN; Jang G; Zhao B
    J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RF - Brentuximab as Treatment for CD30
    Morgado-Carrasco D; Combalia A; Estrach Panella T
    Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.